Logo Image
News|Articles|December 28, 2025

​​Psychiatry in 2025: Year in Review

Fact checked by: Tim Smith

In 2025, psychiatry saw major FDA approvals, novel treatments, and pivotal clinical updates that are transforming care for depression, ADHD, schizophrenia, and anxiety.

The year 2025 brought major advances in psychiatry, including US Food & Drug Administration (FDA) approvals of esketamine for treatment-resistant depression, expanded-use buprenorphine and risperidone injectables, and BrainsWay’s Deep TMS for adolescents with major depressive disorder (MDD), offering clinicians new tools for personalized, effective care.